An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for schedules of controlled substances and providing for tianeptine-related adverse health events.

SB 946 adds tianeptine - a medication sometimes used for depression but with abuse risks - to Pennsylvania's Schedule II of controlled substances, placing it in a high-risk category due to its potential for abuse and dependence. The bill requires the Pennsylvania Department of Health to monitor tianeptine-related health issues (like overdoses, seizures, or withdrawal symptoms) by collecting data from hospitals, poison control centers, and law enforcement. It also empowers the department to issue public safety advisories and establish reporting rules for healthcare providers. This directly affects tianeptine users, healthcare facilities, and public health officials, focusing on tracking health impacts rather than restricting access immediately. The bill takes effect 60 days after enactment.